Worth reading
36Immaterial
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Mixed performance
Direction inferred from the company’s description.Scale
—
Displayed only when the document provides numerical figures.Wording
Avoiding a definitive answer
How definitive the wording is.Contents of this document
Supplementary materials to the earnings reportFirst quarter of the fiscal year ended March 20264 items taken from the company’s own explanation
Financial Results Figures (The key points of this material are explained below)
Net Sales¥1,269,509 thousand+74.0%
Operating profit¥216,506 thousand+117.0%
Ordinary income¥203,670 thousand+116.0%
Net income¥197,902 thousand+126.0%
Selling, general and administrative expenses¥214,883 thousand
Results for the three months of the current quarterFor the consolidated results for the three months of the first quarter of FY2026 (April–June): revenue of ¥1,269,509 thousand, gross profit of ¥431,389 thousand, operating income of ¥216,506 thousand, ordinary income of ¥203,670 thousand, and net income for the quarter of ¥197,902 thousand
Full-year earnings forecast
Net Sales
5,000,000～6,000,000
Operating profit
100,000～600,000
What the company explained in this material
Self-assessment against the planThe company's self-assessment against its own plan.
In line with planAssumptions Underlying the Business OutlookThe assumptions used by the company in preparing its forecast.
Exchange rate¥160/USD
New initiatives
- Adding manufacturing sites and expanding production capacity to improve the profitability and supply stability of certain biosimilar active pharmaceutical ingredients and other products
- Joint development of new biosimilars with Alfresa Holdings Corporation and カイオム社
- Development of a domestic manufacturing facility in Akita Prefecture and expansion of the CDMO business by アルフェナックス バイオロジクス㈱
- Preparation for domestic clinical trials for cerebral palsy with Mochida Pharmaceutical Co.,Ltd.
- Preparation for establishing a new company in the United States and raising funds with Treehill Partners
- Development of cell therapy manufacturing processes with Corning and NIPRO CORPORATION
Key KPIsA metric the company considers important as a management benchmark.
- Number of patients enrolled in Nagoya University clinical research3 cases
- Number of meetings held with domestic and overseas institutional investorsMore than doubled versus FY2024Year on year against the same period last yearMore than doubled versus FY2024
| Item | Details |
|---|---|
| Document type | Supplementary materials to the earnings report |
| Fiscal Period Covered | First quarter of the fiscal year ended March 2026 |
| Net Sales | ¥1,269,509 thousand (YoY +74.0%) |
| Operating profit | ¥216,506 thousand (YoY +117.0%) |
| Ordinary income | ¥203,670 thousand (YoY +116.0%) |
| Net income | ¥197,902 thousand (YoY +126.0%) |
| Selling, general and administrative expenses | ¥214,883 thousand |
| Results for the three months of the current quarter | For the consolidated results for the three months of the first quarter of FY2026 (April–June): revenue of ¥1,269,509 thousand, gross profit of ¥431,389 thousand, operating income of ¥216,506 thousand, ordinary income of ¥203,670 thousand, and net income for the quarter of ¥197,902 thousand |
| Full-year earnings forecast | Net Sales 5,000,000～6,000,000 / Gross profit Not disclosed / Operating profit 100,000～600,000 |
| Self-assessment against the plan | In line with plan |
| Key KPIs | Indicator name Number of patients enrolled in Nagoya University clinical research / Value 3 cases / Year on year against the same period last year Not disclosed, Indicator name Number of meetings held with domestic and overseas institutional investors / Value More than doubled versus FY2024 / Year on year against the same period last year More than doubled versus FY2024 |
| Assumptions Underlying the Business Outlook | Exchange rate ¥160/USD |
| New initiatives | Adding manufacturing sites and expanding production capacity to improve the profitability and supply stability of certain biosimilar active pharmaceutical ingredients and other products, Joint development of new biosimilars with Alfresa Holdings Corporation and カイオム社, Development of a domestic manufacturing facility in Akita Prefecture and expansion of the CDMO business by アルフェナックス バイオロジクス㈱, Preparation for domestic clinical trials for cerebral palsy with Mochida Pharmaceutical Co.,Ltd., Preparation for establishing a new company in the United States and raising funds with Treehill Partners, Development of cell therapy manufacturing processes with Corning and NIPRO CORPORATION |
Items this document does not state (18)
Gross Profit MarginOperating profit marginProgress against full-year forecastSegment resultsBreakdown of Factors Affecting the ChangeUnit price and quantity metricsNumber of stores and locationsNumber of employeesRisk amount incorporated into the outlookMedium-term management plan targetsFinancial targetsAnnual DividendPayout ratioAcquisition of treasury sharesCapital expendituresOrders received and order backlogMarket Size / ShareKey points of the Q&A
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Revenue declined due to lower deliveries of certain active pharmaceutical ingredients and other products. On the earnings side, although manufacturing costs increased due to the weaker yen and product mix changes had an impact, the gross profit margin improved through supply price revisions and the switch to products with lower manufacturing costs. Research and development expenses and other selling, general and administrative expenses decreased year on year, resulting in higher operating income and net income for the quarter.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.